Drug Profile
ZN c5
Alternative Names: ZN-c5Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Zeno Alpha
- Developer Zeno Alpha; Zentalis Pharmaceuticals; Zentera Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease) in USA (PO)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in New Zealand (PO)
- 22 Dec 2022 Zeno Alpha completes phase-I/II clinical trial in Breast cancer (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in Hungary, Russia, Czech Republic, Belarus, USA, Bosnia and Herzegovina, Lithuania, Bulgaria, Serbia and Ukraine (PO) (NCT03560531)